NOVO NORDISK AND SANGAMO BIOSCIENCES ANNOUNCE AGREEMENT

Novo Nordisk A/S and Sangamo BioSciences, Inc. today announced an agreement that provides Novo Nordisk with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology. Sangamo will provide its ZFP technology for Novo Nordisk to evaluate for use in the field of enhanced protein production. "Novo Nordisk recognizes the need for innovative technologies that aid in the rapid development of novel therapies to combat disease," said Esper Boel, Vice-President and Head of Biotechnology of Novo Nordisk. "We look forward to evaluating Sangamo's proprietary technology for enhanced protein production."

Finanzen.net (http://finanzen.net/news/news_detail.asp?NewsNr=332688)